{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975667",
  "id": "02975667",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwygggfj5k9.pdf",
  "summary": "- **Revenue milestone**: FY revenue reached **$208 million**, exceeding $200 million for the first time.  \n- **Geographic expansion**: Strong Australasian sales ($181M); progress in North America (US & Canada), Europe, Asia, and Africa.  \n  - **US/Canada**: Launched Maxigesic IV/tablet; combined addressable market **>US$8 billion**.  \n- **Product pipeline**: 8 patented products in R&D, 24 off-patent injectables, and 5 advanced programs nearing commercialization.  \n- **Financials**: Net debt reduced to **$14.5M** (from $16.2M); dividend increased to **1.8cps** (from 1.6cps).  \n- **FY27 target**: Ambitious **$300M revenue goal**, driven by market expansion and R&D.  \n- **Share price disconnect**: Management believes current valuation undervalues growth prospects.  \n\n*Omitted: Governance updates, operational details, and non-material strategic commentary.*",
  "usage": {
    "prompt_tokens": 1984,
    "completion_tokens": 216,
    "total_tokens": 2200,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:59:19.518191"
}